There is evidence that depression itself can increase risk for preeclampsia. In women with more severe depression, treatment with an SSRI antidepressant may decrease risk.
The current study observed no significant differences in overall developmental outcomes or behavior in exposed versus unexposed children.
More study is needed regarding the safety of sedative-hypnotic medications during pregnancy.
Dr. Marlene Freeman recently shared her insights on Psychiatric Medications and Considerations for Individuals Across Pregnancy, the Postpartum, and Reproductive Years with the National Alliance on Mental Illness on March 7, 2024.
At 7 years of age, children exposed to maternal depression during pregnancy or SSRI antidepressants exhibited similar changes in white matter architecture.
This register-based cohort study from Denmark of 503,158 clinically recognized pregnancies observed little or no risk of teratogenesis associated with first trimester exposure to antipsychotic medications.
Prenatal exposure to prescription stimulants was not associated with an increased risk of neurodevelopmental disorders in exposed children.
There are many different sources of information, some better than others.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on December 14, 2023.
More study is needed regarding the safety of trazodone for the treatment of insomnia during pregnancy.
